State of Alaska Department of Revenue grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1,205.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,645 shares of the biopharmaceutical company’s stock after acquiring an additional 147,415 shares during the period. State of Alaska Department of Revenue’s holdings in Bristol-Myers Squibb were worth $9,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of BMY. Atlantic Trust LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter worth $111,000. Massey Quick Simon & CO. LLC boosted its holdings in Bristol-Myers Squibb by 523.5% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. Blue Chip Partners Inc. boosted its holdings in Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 15 shares during the period. Horan Capital Advisors LLC. bought a new position in Bristol-Myers Squibb in the 3rd quarter worth $122,000. Finally, BDO Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $123,000. 71.55% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have commented on BMY shares. Citigroup set a $72.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a report on Tuesday, December 5th. BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a report on Monday, December 11th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a report on Friday, December 22nd. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $66.30.
Bristol-Myers Squibb Co (BMY) opened at $66.68 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05. The stock has a market cap of $110,117.72, a P/E ratio of 22.41, a PEG ratio of 2.07 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the firm earned $0.63 earnings per share. analysts predict that Bristol-Myers Squibb Co will post 3.2 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.40%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.
ILLEGAL ACTIVITY NOTICE: This piece was published by Week Herald and is owned by of Week Herald. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://weekherald.com/2018/03/14/bristol-myers-squibb-co-bmy-shares-bought-by-state-of-alaska-department-of-revenue.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.